OHB's Billion-Euro SES Contract Can't Break the Share Price Out of Its Slump
Published on 09/04/2026 at 11:11 | Editorial boerse-global.de
The disconnect between OHB's order book and its share price is becoming hard to ignore. Last Tuesday, the Bremen-based space group booked a contract worth just under €1 billion from SES to build 18 satellite platforms for Europe's IRIS² connectivity programme — yet the stock has barely stirred since, adding a mere 0.9 percent.
That muted response looks all the more striking given the scale of the deal. IRIS² ranks among the most strategically significant initiatives in European spaceflight, and for a company of OHB's size, an order of this magnitude provides years of production visibility. Several German-language outlets, including Manager Magazin, framed the contract as a cornerstone of the planned European satellite network. Reuters went further, calling it the most important near-term catalyst for the shares.
So why hasn't it moved the needle? The answer lies in the technical picture. The IRIS² announcement landed on a stock that has spent weeks consolidating, and the chart-based weakness has so far proven stronger than the fundamental news flow. At the time of the primary report, the shares were changing hands at €184.60, down 1.0 percent on the day and off 3.4 percent on the week. The secondary report, tracking a slightly different window, showed the stock closing at €186.40 after a 4.6 percent daily gain — evidence that investors will reward individual positive headlines, but that broader confidence has yet to return.
Should investors sell immediately? Or is it worth buying OHB SE?
The gap between the operational story and the market's mood is starkly visible in the longer-term figures. OHB's shares currently sit roughly 73 percent below their 52-week high of €688.00, reached back in May. Annualised volatility of 77 percent underscores just how jittery trading in the name has become. A relative strength index of 34.9 points to oversold conditions, though that signals selling pressure rather than guaranteeing an imminent reversal.
Part of the explanation lies in a structural overhang that predates the SES deal. The capital increase resolved more than a month ago continues to weigh on the share price, and analysts see it as a key reason why the equity has failed to reflect the improving order situation. The stock's elevation to the SDax roughly three weeks ago — taking the slot vacated by Klöckner — generated a brief burst of attention but did nothing to arrest the downward trend.
There is, however, reason to believe the market's scepticism may soon be tested. Oddo BHF analysts upgraded OHB from "Neutral" to "Buy" at the end of August, just days before the IRIS² contract was announced — a call that now looks prescient and is drawing renewed scrutiny as the share price softens. The company itself signalled in early August, per dpa, that it expected further growth in the second half of the year, a projection the SES order lends considerable weight to.
The real test arrives on 12 November, when OHB publishes its third-quarter figures. Only then will investors learn whether the IRIS² contract is beginning to show up in the order backlog and revenue planning, and whether management can confirm expectations on margins and cash flow. Until that day, the stock looks set to remain caught between an exceptionally strong operational narrative and a technical consolidation that refuses to loosen its grip.
Ad
OHB SE Stock: New Analysis - 4 September
Fresh OHB SE information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
